source
- FDA advisory panel backs experimental Replimune melanoma therapy after two prior rejectionsAn FDA advisory committee voted 10‑to‑3 to recommend the use of an experimental Replimune treatment for patients with advanced melanoma. The panel’s recommendation marks a shift after the agency p…
- Trump administration revises 340B rebate pilot, sparking hospital backlashThe Health Resources and Services Administration announced a revision to the 340B drug pricing program’s rebate pilot, slated to begin on Jan 1, 2027. Under the new rules, participating manufactur…